ΒΙΒΛΙΟΓΡΑΦΙΑ

1. Johnson RW, Wasner G, Saddier P et al. Postherpetic Neuralgia: epidemiology, pathology and management. Expert Rev Neurothen 2007;7: 1581-95.

2. Arvin A. Aging, immunity, and the varicella zoster virus. N. Engl J Med 2005;352:2266-67.

3. Oxman MN. Zoster Vaccine: Current Status and Future Prospects Clinical Infectious Diseases 2010;52(2): 197-213.

4. Johnson RW. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination Aging Clin Exp Res 2009;21: 236-243.

5. Burke BL: Steele RW; Beard OW; Wood JS; Cain TD; Marmer DJ. Immune Responses to Varicalla-Zoster in the Aged. Arch Intern Med 1982; 42:291-293.

6. Browsher D. The lifetime occurrence of Herpes Zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 1999;3: 335-42.

7. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and xontrol of varicella-zosterin- fection Rev Med Micro 1993;4: 222-30.

8. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan Sm. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014;348:g2911.

9. Hope-Simpson RE. Postherpetic neuralgia. JR Coll Gen Practice 1975;25: 571-5.

10. Johnson RW et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:1-13.

11. Helgason S, Petursson G, Gudmundsson S et al. Prevalence of postherpetic neuralgia after a single episode of herpes zoster: prospective study with long term follow up. Br Med J 2000; 321: 1-4.

12. Johnson RW. Zoster associated pain: what is known, who is at risk and how can it be managed? Herpes 2007;14 (s2): 30A-34A.

13. Weinke T et al. Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey J Public Health 2010;18(4): 367-374.

14. Drolet M et al. The impact of herpes zoster and postherpetic neuralgia CMAJ 2010;N/A: DOI:10.1503/cmaj.091711.

15. Drolet M. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. Vaccine 2012;30:2047-50.

16. Cunningham AL, Breuer J, Dwyer DE et al. The prevention and management of herpes zoster. Med J Aust 2008;188: 171-6.

17. Pavan-Langston D.Ophthalmic zoster. In: Arvin AM, Gershon AA eds. Varicella-Zoster virus – Virology and clinical management. Cambridge: Cambridge University Press; 2000;N/A: p276-98.

18. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella-Zoster Virus. Virology and clinical management. Cambridge: Cambridge University Press; 2000. p. 246-75.

19. Galil K et al. The sequelae of Herpes Zoster. Arch Intern Med 1997; 157: 1209-1213.

20. Johnson R, McElhaney J, Pedalino B et al, Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis (Supplement) 2007; 11 S2:S43-S48.

21. Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39(3):342–348

22. Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997-2006. Infection. 2014;42:729-35.

23. Harpaz R et al. Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR. 2008;RR-5):1–30.

24. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–354.

25. Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79(2):231–252

26. Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis. 2002;186(suppl 1):S83–S90.

27. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349.

28. Εγκύκλιος με θέμα “Πρόγραμμα εμβολιασμών ενηλίκων”, Υπουργείο Υγείας, Γενική Διεύθυνση Δημόσιας Υγείας, Αρ. Πρωτ. Γ1α/Γ.Π.οικ.38872, Αθήνα, 23/5/2017.

29. Φύλλο Οδηγιών Χρήσης Zostavax, Ιούλιος 2017

Με την ευγενική χορηγία της:ΕΡΠΗΣ ΖΩΣΤΗΡΑΣ ΕΜΒΟΛΙΟ

ΕΡΠΗΣ ΖΩΣΤΗΡΑΣ ΕΜΒΟΛΙΟ

Υπό την αιγίδα:ΕΡΠΗΣ ΖΩΣΤΗΡΑΣ ΕΜΒΟΛΙΟΕΡΠΗΣ ΖΩΣΤΗΡΑΣ ΕΜΒΟΛΙΟ